|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Erhard F, Haas J, Lieber D, Malterer G,
Jaskiewicz L, Zavolan M, Dölken L and Zimmer R: Widespread context
dependency of microRNA-mediated regulation. Genome Res. 24:906–919.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tong AW and Nemunaitis J: Modulation of
miRNA activity in human cancer: A new paradigm for cancer gene
therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen DL, Zhang DS, Lu YX, Chen LZ, Zeng
ZL, He MM, Wang FH, Li YH, Zhang HZ, Pelicano H, et al:
microRNA-217 inhibits tumor progression and metastasis by
downregulating EZH2 and predicts favorable prognosis in gastric
cancer. Oncotarget. 6:10868–10879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Zhao J, Zhang JW, Huang QY, Huang
JZ, Chi LS, Tang HJ, Liu GQ, Zhu DJ and Ma WM: MicroRNA-217,
down-regulated in clear cell renal cell carcinoma and associated
with lower survival, suppresses cell proliferation and migration.
Neoplasma. 60:511–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Q, Yuan Y, Cui J, Xiao T and Jiang
D: MiR-217 promotes tumor proliferation in breast cancer via
targeting DACH1. J Cancer. 6:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. Jul 10–2015.Epub
ahead of print.
|
|
15
|
King SM, Modi DA, Eddie SL and Burdette
JE: Insulin and insulin-like growth factor signaling increases
proliferation and hyperplasia of the ovarian surface epithelium and
decreases follicular integrity through upregulation of the
PI3-kinase pathway. J Ovarian Res. 6:122013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.
|
|
17
|
Di Leva G and Croce CM: The role of
microRNAs in the tumorigenesis of ovarian cancer. Front Oncol.
3:1532013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen C, Liu X, Ma H, Zhang W and Li H:
miR-338-3p suppresses tumor growth of ovarian epithelial carcinoma
by targeting Runx2. Int J Oncol. 46:2277–2285. 2015.PubMed/NCBI
|
|
19
|
Lin J, Zhang L, Huang H, Huang Y, Huang L,
Wang J, Huang S, He L, Zhou Y, Jia W, et al: MiR-26b/KPNA2 axis
inhibits epithelial ovarian carcinoma proliferation and metastasis
through downregulating OCT4. Oncotarget. 6:23793–23806. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew
KP, Wu YL and Zhang S: MiR-373 targeting of the Rab22a oncogene
suppresses tumor invasion and metastasis in ovarian cancer.
Oncotarget. 5:12291–12303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su J, Wang Q, Liu Y and Zhong M: miR-217
inhibits invasion of hepatocellular carcinoma cells through direct
suppression of E2F3. Mol Cell Biochem. 392:289–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei R, Deng Z and Su J: miR-217 targeting
Wnt5a in osteosarcoma functions as a potential tumor suppressor.
Biomed Pharmacother. 72:158–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang B, Shen ZL, Jiang KW, Zhao G, Wang
CY, Yan YC, Yang Y, Zhang JZ, Shen C, Gao ZD, et al: MicroRNA-217
functions as a prognosis predictor and inhibits colorectal cancer
cell proliferation and invasion via an AEG-1 dependent mechanism.
BMC Cancer. 15:4372015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishioka C, Ikezoe T, Yang J, Nobumoto A,
Tsuda M and Yokoyama A: Downregulation of miR-217 correlates with
resistance of Ph (+) leukemia cells to ABL tyrosine kinase
inhibitors. Cancer Sci. 105:297–307. 2014. View Article : Google Scholar
|
|
26
|
de Yébenes VG, Bartolomé-Izquierdo N,
Nogales-Cadenas R, Pérez-Durán P, Mur SM, Martínez N, Di Lisio L,
Robbiani DF, Pascual-Montano A, Cañamero M, et al: miR-217 is an
oncogene that enhances the germinal center reaction. Blood.
124:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao S, Qiu Z, He J, Li L and Li W:
Insulin-like growth factor receptor 1 (IGF1R) expression and
survival in non-small cell lung cancer patients: A meta-analysis.
Int J Clin Exp Pathol. 7:6694–6704. 2014.PubMed/NCBI
|
|
28
|
Blakesley VA, Stannard BS, Kalebic T,
Helman LJ and LeRoith D: Role of the IGF-I receptor in mutagenesis
and tumor promotion. J Endocrinol. 152:339–344. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frasca F, Pandini G, Sciacca L, Pezzino V,
Squatrito S, Belfiore A and Vigneri R: The role of insulin
receptors and IGF-I receptors in cancer and other diseases. Arch
Physiol Biochem. 114:23–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gotlieb WH, Bruchim I, Gu J, Shi Y,
Camirand A, Blouin MJ, Zhao Y and Pollak MN: Insulin-like growth
factor receptor I targeting in epithelial ovarian cancer. Gynecol
Oncol. 100:389–396. 2006. View Article : Google Scholar
|
|
32
|
King ER, Zu Z, Tsang YT, Deavers MT,
Malpica A, Mok SC, Gershenson DM and Wong KK: The insulin-like
growth factor 1 pathway is a potential therapeutic target for
low-grade serous ovarian carcinoma. Gynecol Oncol. 123:13–18. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wen XP, Ma HL, Zhao LY, Zhang W and Dang
CX: MiR-30a suppresses non-small cell lung cancer progression
through AKT signaling pathway by targeting IGF1R. Cell Mol Biol
(Noisy-le-grand). 61:78–85. 2015.
|
|
34
|
Su J, Liang H, Yao W, Wang N, Zhang S, Yan
X, Feng H, Pang W, Wang Y, Wang X, et al: MiR-143 and MiR-145
regulate IGF1R to suppress cell proliferation in colorectal cancer.
PLoS One. 9:e1144202014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu W, Hang M, Yuan CY, Wu FL, Chen SB and
Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by
targeting insulin-like growth factor 1 receptor in human non-small
cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870.
2015.PubMed/NCBI
|
